SiteOne Therapeutics

OverviewSuggest Edit

SiteOne Therapeutics, headquartered in Bozeman, Montana with a research team in San Francisco, California, is dedicated to developing novel pain therapeutics to safely, effectively and efficiently treat acute and chronic pain without the limitations of existing drugs, such as opioids. The company’s therapeutic candidates are highly selective sodium ion channel 1.7 (NaV1.7) inhibitors based on naturally occurring small molecules. Given the critical role that NaV1.7 plays in the generation and conduction of pain signals, combined with the urgent need for new, non-opioid pain therapies, SiteOne is focused on advancing its lead products to serve patients that suffer from moderate to severe pain.
TypePrivate
Founded2010
HQBozeman, MT, US
Websitesiteonetherapeutics.com

Latest Updates

Cybersecurity ratingAMore

Key People/Management at SiteOne Therapeutics

Stan E. Abel

Stan E. Abel

President and Chief Executive Officer
Debra Odink

Debra Odink

Chief Development Officer
Du Bois

Du Bois

Director
John Mulcahy

John Mulcahy

Co-Inventor, VP of Research
Lowell Sears

Lowell Sears

Chairman of the Board
Hassan Pajouhesh

Hassan Pajouhesh

Director, Chemistry
Show more

SiteOne Therapeutics Office Locations

SiteOne Therapeutics has an office in Bozeman
Bozeman, MT, US (HQ)
351 Evergreen Dr Suite B-1
Show all (2)

SiteOne Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2010

SiteOne Therapeutics total Funding

$17.8 m

SiteOne Therapeutics latest funding size

$15 m

Time since last funding

4 years ago

SiteOne Therapeutics investors

SiteOne Therapeutics's latest funding round in January 2017 was reported to be $15 m. In total, SiteOne Therapeutics has raised $17.8 m
Show all financial metrics

SiteOne Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

SiteOne Therapeutics Online and Social Media Presence

Embed Graph

SiteOne Therapeutics News and Updates

SiteOne Therapeutics Appoints Scott Braunstein, MD to Board of Directors

BOZEMAN, Mont., Sept. 11, 2018 /PRNewswire/ -- SiteOne Therapeutics, a private biopharmaceutical company advancing novel non-opioid pain therapeutics, today announced that Scott Braunstein, MD has been appointed to the Company's Board of Directors. Dr. Braunstein brings extensive...

SiteOne Therapeutics Blogs

SiteOne Announces Award of $5.3M Federal Grant from NIH / NIDA for the Development of a Novel Non-Opioid Analgesic

Award intended to fund non-clinical and clinical activities through Phase 2 Proof of Concept in Post-operative Pain ManagementBOZEMAN, Mont., October 10, 2019 /PRNewswire/ -- SiteOne Therapeutics, a privately-held biopharmaceutical company advancing novel non-opioid pain therapeutics, today announce…

SiteOne Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference on Monday, March 11

BOZEMAN, Mont., March 7, 2019 /PRNewswire/ -- SiteOne Therapeutics, a private biopharmaceutical company advancing novel non-opioid pain therapeutics, today announced that Stan Abel, President and Chief Executive Officer, will present at the Cowen and Company 39th Annual Healthcare Conference on Mond…

SiteOne Therapeutics Receives NIH Grant to Support the Development of Novel Therapeutics to Treat Ocular Pain

Potential applications in pain associated with ocular surgery, injury, and Dry Eye Syndrome BOZEMAN, Montana, Sept. 25, 2018 /PRNewswire/ -- SiteOne Therapeutics, a private biopharmaceutical company advancing novel non-opioid pain therapeutics, today announced the company has been awarded a $1.4 mil…

SiteOne Therapeutics Appoints John Hunter, Ph.D. as Chief Scientific Officer

BOZEMAN, Montana, September 6th, 2018 — SiteOne Therapeutics, a private biopharmaceutical company advancing novel non-opioid pain therapeutics, today announced the appointment of John Hunter, Ph.D., as Chief Scientific Officer. Dr. Hunter is a highly-accomplished pharmaceutical research and developm…

SiteOne Therapeutics Frequently Asked Questions

  • When was SiteOne Therapeutics founded?

    SiteOne Therapeutics was founded in 2010.

  • Who are SiteOne Therapeutics key executives?

    SiteOne Therapeutics's key executives are Stan E. Abel, Debra Odink and Du Bois.

  • Who are SiteOne Therapeutics competitors?

    Competitors of SiteOne Therapeutics include U.S. Stem Cell, Enanta Pharmaceuticals and Pfenex.

  • Where is SiteOne Therapeutics headquarters?

    SiteOne Therapeutics headquarters is located at 351 Evergreen Dr Suite B-1, Bozeman.

  • Where are SiteOne Therapeutics offices?

    SiteOne Therapeutics has an office in Bozeman.

  • How many offices does SiteOne Therapeutics have?

    SiteOne Therapeutics has 2 offices.